U.S. FDA grants Breakthrough Therapy Designation for IPN60340 in first-line unfit acute myeloid leukemia
The U.S. Food and Drug Administration granted Breakthrough Therapy Designation to IPN60340 given with venetoclax and azacitidine for first-line unfit acute myeloid leukemia, based on early Phase I/II EVICTION trial data. Ipsen plans to discuss Phase II/III development plans with the FDA in the first half of 2026.
